Sustainable Delivery Systems Through Green Nanotechnology

Krishnaswamy, Kiruba; Orsat, Valérie

doi:10.1016/b978-0-323-52727-9.00002-9

Cited by 36 publications

(19 citation statements)

References 78 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In the top-down strategy the NPs are obtained from preformed polymers, while the polymerization is achieved during NP formulation in bottom-up strategies [21].…”

Section: Introductionmentioning

confidence: 99%

An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

Nanoparticles (NPs) are promising drug delivery systems (DDS) for identifying and treating cancer. Active targeting NPs can be generated by conjugation with ligands that bind overexpressed or mutant cell surface receptors on target cells that are poorly or not even expressed on normal cells. Receptor-mediated endocytosis of the NPs occurs and the drug is released inside the cell or in the surrounding tissue due to the bystander effect. Antibodies are the most frequently used ligands to actively target tumor cells. In this context, antibody-based therapies have been extensively used in HER2+ breast cancer. However, some patients inherently display resistance and in advanced stages, almost all eventually progress. Functionalized NPs through conjugation with antibodies appear to be a promising strategy to optimize targeted therapies due to properties related to biocompatibility, suitable delivery control and efficiency of functionalization. This review is focused on the different strategies to conjugate antibodies into polymeric NPs. Recent antibody conjugation approaches applied to the improvement of breast cancer therapy are highlighted in this review.

show abstract

“…In the top-down strategy the NPs are obtained from preformed polymers, while the polymerization is achieved during NP formulation in bottom-up strategies [21].…”

Section: Introductionmentioning

confidence: 99%

An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Polymer nanoparticles (P-NPs) are the most widely used nanocarriers in the pharmaceutical sector to develop controlled, sustained and burst drug delivery systems with release profiles directly related to the constructed polymeric shell. P-NPs can be either nanospheres or nanocapsules, with particle size (PS) ranging from 1 to 1000 nm and two fundamental preparation techniques, including “top-down” and “bottom-up” methods [ 75 , 76 , 77 ]. They can be used to mask the taste and to protect drug/compounds from environmental and gastric degradation, offering enhanced bioavailability, increased stability of any volatile materials with non-immunogenicity, and a low to nontoxicity nature [ 78 , 79 ].…”

Section: Opportunities and Limitations Of Nanosystems For Mafld Thmentioning

confidence: 99%

The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update

2021

View full text Add to dashboard Cite

Current research indicates that the next silent epidemic will be linked to chronic liver diseases, specifically non-alcoholic fatty liver disease (NAFLD), which was renamed as metabolic-associated fatty liver disease (MAFLD) in 2020. Globally, MAFLD mortality is on the rise. The etiology of MAFLD is multifactorial and still incompletely understood, but includes the accumulation of intrahepatic lipids, alterations in energy metabolism, insulin resistance, and inflammatory processes. The available MAFLD treatment, therefore, relies on improving the patient’s lifestyle and multidisciplinary pharmacotherapeutic options, whereas the option of surgery is useless without managing the comorbidities of the MAFLD. Nanotechnology is an emerging approach addressing MAFLD, where nanoformulations are suggested to improve the safety and physicochemical properties of conventional drugs/herbal medicines, physical, chemical, and physiological stability, and liver-targeting properties. A wide variety of liver nanosystems were constructed and delivered to the liver, only those that addressed the MAFLD were discussed in this review in terms of the nanocarrier classes, particle size, shape, zeta potential and offered dissolution rate(s), the suitable preparation method(s), excipients (with synergistic effects), and the suitable drug/compound for loading. The advantages and challenges of each nanocarrier and the focus on potential promising perspectives in the production of MAFLD nanomedicine were also highlighted.

show abstract

“…24 Considering the abovementioned categories for fabrication methods, top-down methods are solvent emulsification-evaporation (emulsion evaporation method), solvent emulsification-diffusion (emulsion diffusion method), nanoprecipitation (solvent displacement method), salting out, dialysis, and supercritical fluid technology (SCF). 25 In addition, the most frequently used bottom-up methods are emulsion polymerization and recombinant DNA technology. 26 Here, some of the most frequent used methods have been discussed.…”

Section: Polymeric Nanoparticlesmentioning

confidence: 99%

“…There are quite a few drying methods available, some of the most important of which are atmospheric freeze drying, spray freeze drying, vacuum freeze drying, and lyophilization 24 . Considering the abovementioned categories for fabrication methods, top‐down methods are solvent emulsification‐evaporation (emulsion evaporation method), solvent emulsification‐diffusion (emulsion diffusion method), nanoprecipitation (solvent displacement method), salting out, dialysis, and supercritical fluid technology (SCF) 25 . In addition, the most frequently used bottom‐up methods are emulsion polymerization and recombinant DNA technology 26 .…”

Section: Polymeric Carriers Structuresmentioning

confidence: 99%

Polymeric nanocarriers in targeted drug delivery systems: A review

Abasian

Ghanavati

Rahebi

et al. 2020

Polymers for Advanced Techs

View full text Add to dashboard Cite

Today's medicine mainly relies on conventional means of therapeutics delivery to the human body, such as tablets, capsules, syrups, and injectable drugs. Utilizing such techniques are associated with a number of drawbacks including the need of high drug dosage, causing transient drug concentration changes in the patient's body, poor solubility, poor bioavailability, drug degradation, and interaction with the biological environment (enzymes and proteins). To address these issues, nanotechnology-based novel drug delivery methods are proposed. Among the plethora of novel drug delivery techniques, the use of polymeric nanocarriers is shown to be promising. In fact, they focus on three main questions: first, where should a drug be released? Second, when should the drug be released? And finally, how should the drug be released? In this review, we are confined to explaining some concepts regarding to polymeric nanocarriers. First, different kinds of polymeric nanocarriers have been explained, in terms of their structures and properties. Second, different fabrication methods, for each one, have been elaborated. Finally, a handful of works carried out have been reviewed for their special structure, their kind of polymers which is used, and the drug which is encapsulated.

show abstract

Sustainable Delivery Systems Through Green Nanotechnology

Cited by 36 publications

References 78 publications

An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy

An Overview of Antibody Conjugated Polymeric Nanoparticles for Breast Cancer Therapy

The Evaluation of Drug Delivery Nanocarrier Development and Pharmacological Briefing for Metabolic-Associated Fatty Liver Disease (MAFLD): An Update

Polymeric nanocarriers in targeted drug delivery systems: A review

Contact Info

Product

Resources

About